Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections

American Journal of Therapeutics

Volumn 19, Issue 1, 2012, Pages 51-63

  Lewis, Russell E ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

antifungal therapy; azoles; echinocandins; invasive fungal infections; pharmacokinetics; polyenes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYTOCHROME P450 2C19; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FUSARIUM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INVASIVE ASPERGILLOSIS; LEUKEMIA; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MUCORALES; MUCORMYCOSIS; NONHUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SCEDOSPORIUM; SYSTEMIC MYCOSIS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; HUMANS; MYCOSES; PHARMACOGENETICS; TISSUE DISTRIBUTION;

EID: 84855663620     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181ff7e10     Document Type: Review

References (44)

1. Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;32:1319-1324. (Pubitemid 32405904)
2. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006;43:S3-S14. (Pubitemid 44078892)
3. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-643. (Pubitemid 37100802)
4. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317. (Pubitemid 39050477)
5. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006;91: 986-989. (Pubitemid 44023159)
6. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994;38:1422-1424. (Pubitemid 24170733)
7. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002;35:627-630.
8. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172-1177. (Pubitemid 37372504)
9. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol. 2005;26:540-547. (Pubitemid 40896144)
10. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232-1239. (Pubitemid 41532664)
11. Denning DW, Marinus A, Cohen J, et al. EORTC invasive fungal infections cooperative group. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J Infect. 1998;37:173-180. (Pubitemid 28482922)
12. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48:265-273.
13. Iwen PC, Rupp ME, Langnas AN, et al. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis. 1998;26:1092-1097. (Pubitemid 28215471)
14. Marr KA. Empirical antifungal therapy-new options, new tradeoffs. N Engl J Med. 2002;346:278-280. (Pubitemid 34438868)
15. Torres HA, Rivero GA, Lewis RE, et al. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2003;46:25-28. (Pubitemid 36556017)
16. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-366. (Pubitemid 32173620)
17. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33:1824-1833. (Pubitemid 33105120)
18. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95: 644-650.
19. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin North Am. 2002;16:915-933. (Pubitemid 35477519)
20. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008; 47:503-509.
21. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillusactive antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350-1360.
22. Ritz N, Ammann RA, Aebischer CC, et al. Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. Eur J Pediatr. 2005;164: 231-235. (Pubitemid 40543793)
23. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584-587. (Pubitemid 39120940)
24. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425-429. (Pubitemid 46487308)
25. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653. (Pubitemid 41170352)
26. Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41:3623-3626. (Pubitemid 36994692)
27. Dodds Ashley E, Lewis R, Lewis J, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43: S28-S39. (Pubitemid 44078894)
28. Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother. 1999;43:1264-1266. (Pubitemid 29214759)
29. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42:4419-4431. (Pubitemid 39362350)
30. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31. (Pubitemid 43939072)
31. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49:3640-3645. (Pubitemid 41233011)
32. Greene RE, Schlamm HT, Oestmann J, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373-379. (Pubitemid 46147619)
33. Von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995;62:341-347.
34. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-147. (Pubitemid 27020567)
35. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19:253-259. (Pubitemid 32063503)
36. Verweij PE, Mennink-Kersten MASH. Issues with galactomannan testing. Med Mycol. 2006;44:179-183. (Pubitemid 44524102)
37. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis. 2007;45: e101-e104. (Pubitemid 47580399)
38. HopeWW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21: 580-586.
39. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24-34.
40. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease Pharmacotherapy. 2007;27:1627-1636. (Pubitemid 350234311)
41. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenousto oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546-2553. (Pubitemid 34793462)
42. Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother. 2005;49:3171-3177. (Pubitemid 41060556)
43. Labelle AJ, Micek ST, Roubinian N, et al. Treatmentrelated risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008;36:2967-2972.
44. Pai MP, Turpin RS, GareyKW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007;51:35-39. (Pubitemid 46047684)